Abstract: Data Integrity Field (DIF) is used to implement compression verification. When a write IO operation is received, the write IO operation is divided into data blocks, and a respective DIF is created and appended to each data block. When the write IO is compressed, the data blocks and respective DIF are collectively compressed to form compressed data. The compressed data is divided into compressed data blocks, and a respective second DIF is created and appended to each respective data block of compressed data. To verify that the compressed data is able to be decompressed, a copy of the compressed data is decompressed to restore the original data blocks and respective DIF. Each respective DIF is used to verify the content of its respective data block. In response to a determination that respective DIF match the respective data blocks, the decompression process is deemed to be verified.

Abstract: A Ransomware Activity Detection System (RADS) characterizes historic read/write IO activity on a storage volume, and also characterizes historic data characteristics of the storage volume, such as the percentage reducibility of the data held in the storage volume. The RADS monitors the storage volume to identify differences between current read/write IO activity and historic read/write IO activity, as well as difference between current data characteristics of the storage volume and historic data characteristics of the storage volume. When the RADS detects a significant difference in read/write IO activity on a storage volume, that is coupled with a significant changes to the data characteristics of the storage volume, the RADS protects the storage volume and generates an alert of the possible occurrence of a ransomware attack. Protection may occur prior in connection with any bulk read operation to proactively protect storage volumes against ransomware attacks.

Abstract: The techniques described herein relate to a method including: executing a self-deduplication process on a first dataset and a second dataset; standardizing the first dataset and the second dataset using a common data model; indexing records from the first dataset and the second dataset in a common index; scoring records in the common index; deduplicating the records in the common index; and storing the records in the common index as a master dataset.

Abstract: The present disclosure provides methods, compositions and kits as well as systems for manipulating nucleic acids, including implementing isothermal amplification, such as recombinase-polymerase amplification (RPA), of a nucleic acid template using a pre-seeded solid support. Provided are rapid and efficient methods for generating template nucleic acid molecules comprising specific nucleotide sequence bound to solid support. Such methods can be used, for example, in manipulating nucleic acids in preparation for analysis methods that utilize monoclonal populations of nucleic acids.

Abstract: Disclosed herein are methods for treating, ameliorating, and/or preventing Alzheimer's Disease in a specific patient population using tramiprosate, valyl-3-amino-1-propanesulfonic acid, or a pharmaceutically acceptable salt thereof, based upon a combination of APOE4 status and disease severity.

Abstract: Disclosed herein are methods and compositions for treating, ameliorating, and/or preventing Alzheimer's disease in ApoE4-postitive patients using particular compounds and compositions thereof.

Abstract: Disclosed herein are methods for treating, ameliorating, and/or preventing Alzheimer's Disease in a specific patient population using tramiprosate, valyl-3-amino-1-propanesulfonic acid, or a pharmaceutically acceptable salt thereof based upon a combination of APOE4 status and disease severity.

Abstract: Disclosed herein are methods for treating, ameliorating, and/or preventing Alzheimer's Disease in a specific patient population using tramiprosate, valyl-3-amino-1-propanesulfonic acid, or a pharmaceutically acceptable salt thereof based upon a combination of APOE4 status and disease severity.

Abstract: Disclosed herein are methods and compositions for treating, ameliorating, and/or preventing Alzheimer's disease in ApoE4-postitive patients using particular compounds and compositions thereof.

Abstract: Disclosed herein are methods and compositions for treating, ameliorating, and/or preventing Alzheimer's disease in ApoE4-postitive patients using particular compounds and compositions thereof.

Abstract: Disclosed herein are methods for treating, ameliorating, and/or preventing Alzheimer's Disease in a specific patient population using tramiprosate, valyl-3-amino-1-propanesulfonic acid, or a pharmaceutically acceptable salt thereof based upon a combination of APOE4 status and disease severity.

Abstract: Disclosed herein are methods and compositions for treating, ameliorating, and/or preventing Alzheimer's disease in ApoE4-postitive patients using particular compounds and compositions thereof.

Abstract: The present invention provides phosphorylated and pyrophosphate derivatives of polyols, and structural derivatives of these compounds, and provides pharmaceutical compositions comprising the same. The compounds and compositions disclosed herein have various biological activities, including for example, as allosteric effectors of hemoglobin and/or as kinase inhibitors. The present invention further provides methods for therapy in human or mammalian patients, and methods for synthesis of biologically active compounds and their intermediates.